NCT01198496

Trial name or title	RESPECT Study
Methods	Multicentre, randomized, parallel, open‐label study. The follow‐up period will be 3 years
Participants	Men and women aged 50 to 85 years, hypertensive patients and history of stroke who satisfy the following criteria: Outpatient; Onset of stroke between 30 days and 3 years before date of consent; Drug adherence ≥ 80% during the screening period; Mean of 2 baseline blood pressure measurements is either 180 > SBP ≥ 130 mmHg or 110 > DBP ≥ 80 mmHg; Cerebral infarction with severity 3 or less on the modified Rankin scale. Exclusion criteria include secondary or severe hypertension, MI or angioplasty within 3 months prior to the screening, current or previous heart failure with NYHA classification class III or more, or ejection fraction < 35%, severe bilateral carotid stenosis or major cerebral artery occlusion, severe paralysis due to stroke, current kidney or liver dysfunction
Interventions	Standard target: < 140/90 mmHg (or < 130/80 if current diabetes, kidney disease or MI) Intensive target: < 120/80 mmHg
Outcomes	Primary outcome measures: prevention of recurrent stroke. Participants on blood pressure treatment achieving their respective blood pressure target will be followed for recurrence of stroke. Secondary outcome measures: Incidence of events other than stroke. Under strict blood pressure control, not only the recurrence of stroke but also occurrence of cardiovascular events (such as MI and heart failure), angioplasty, and death will be reduced
Starting date	October 2010
Contact information	Hiroko Usami, PhD. Biomedis International Ltd. Tfn: 81‐1‐3‐6252‐3282. hiroko‐u@biomedis.co.jp
Notes	Trial website: http://www.respect‐study.com/